These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 12832347)

  • 21. Insulin glargine and incidence of cancer--an ongoing debate.
    Hermanns N; Kulzer B
    J Diabetes Sci Technol; 2010 Mar; 4(2):497-8. PubMed ID: 20307414
    [No Abstract]   [Full Text] [Related]  

  • 22. [Systemic and local allergy to human insulin].
    Wittrup M; Pildal J; Rasmussen AK; Skov BG; Petersen J; Mandrup-Poulsen TR
    Ugeskr Laeger; 2003 May; 165(21):2207-8. PubMed ID: 12820512
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-acting insulin allergy in a diabetic child.
    Mastrorilli C; Rizzuti L; Cangelosi AM; Iovane B; Chiari G; Caffarelli C
    Int J Immunopathol Pharmacol; 2017 Jun; 30(2):174-177. PubMed ID: 28368217
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Good glycemic control with flexibility in timing of basal insulin supply: a 24-week comparison of insulin glargine given once daily in the morning or at bedtime in combination with morning glimepiride.
    Standl E; Maxeiner S; Raptis S; Karimi-Anderesi Z; Schweitzer MA;
    Diabetes Care; 2005 Feb; 28(2):419-20. PubMed ID: 15677803
    [No Abstract]   [Full Text] [Related]  

  • 25. Insulin desensitization with insulin lispro and an insulin pump in a 5-year-old child.
    Eapen SS; Connor EL; Gern JE
    Ann Allergy Asthma Immunol; 2000 Nov; 85(5):395-7. PubMed ID: 11101184
    [TBL] [Abstract][Full Text] [Related]  

  • 26. To: Scholtz HE, Pretorius SG, Wessels DH, Becker RHA (2005) Pharmacokinetic and glucodynamic variability: assessment of insulin glargine, NPH insulin and insulin ultralente in healthy volunteers using a euglycaemic clamp technique. Diabetologia 48:1988-1995.
    DeVries JH
    Diabetologia; 2006 May; 49(5):1125-6. PubMed ID: 16520920
    [No Abstract]   [Full Text] [Related]  

  • 27. A case of human insulin allergy induced by short-acting and intermediate-acting insulin but not by long-acting insulin.
    Adachi A; Fukunaga A; Horikawa T
    Int J Dermatol; 2004 Aug; 43(8):597-9. PubMed ID: 15304187
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The international study of insulin and cancer.
    Grimaldi-Bensouda L; Marty M; Pollak M; Cameron D; Riddle M; Charbonnel B; Barnett AH; Boffetta P; Boivin JF; Evans M; Rossignol M; Benichou J; Abenhaim L;
    Lancet; 2010 Sep; 376(9743):769-70. PubMed ID: 20816540
    [No Abstract]   [Full Text] [Related]  

  • 29. Insulin glargine and cancer.
    Hemkens LG; Bender R; Grouven U; Sawicki PT
    Lancet; 2009 Nov; 374(9703):1743-4; author reply 1744. PubMed ID: 19932352
    [No Abstract]   [Full Text] [Related]  

  • 30. Insufficient evaluation of adverse events is not a proof of safety.
    Hemkens LG; Grouven U; Bender R; Sawicki PT
    Diabetologia; 2010 Apr; 53(4):790-2; author reply 793-4. PubMed ID: 20099058
    [No Abstract]   [Full Text] [Related]  

  • 31. Insulin allergy decreased by Humulin S (Humulin R) and not by insulin aspart or Actrapid Penfill (Penfill R).
    Katahira M; Hara I; Nishizaki T
    Diabet Med; 2005 Oct; 22(10):1455-7. PubMed ID: 16176214
    [No Abstract]   [Full Text] [Related]  

  • 32. [Adverse effects of insulin].
    Noritake M
    Nihon Rinsho; 1997 Nov; 55 Suppl():243-8. PubMed ID: 9434475
    [No Abstract]   [Full Text] [Related]  

  • 33. [Insulin allergy: background, diagnosis and treatment].
    Wonders J; Eekhoff EM; Heine R; Bruynzeel DP; Rustemeyer T
    Ned Tijdschr Geneeskd; 2005 Dec; 149(50):2783-8. PubMed ID: 16385830
    [TBL] [Abstract][Full Text] [Related]  

  • 34. German agency suspects that insulin analogue glargine increases risk of cancer.
    Tuffs A
    BMJ; 2009 Jul; 339():b2774. PubMed ID: 19586980
    [No Abstract]   [Full Text] [Related]  

  • 35. Nausea and vomiting due to insulin glargine in patient with type 1 diabetes mellitus.
    Dixon AN; Bain SC
    BMJ; 2005 Feb; 330(7489):455. PubMed ID: 15731143
    [No Abstract]   [Full Text] [Related]  

  • 36. Insulin glargine and cancer: another side to the story?
    Gale EA
    Lancet; 2009 Aug; 374(9689):521. PubMed ID: 19683632
    [No Abstract]   [Full Text] [Related]  

  • 37. Comparative trial between insulin glargine and NPH insulin in children and adolescents with type 1 diabetes.
    Schober E; Schoenle E; Van Dyk J; Wernicke-Panten K;
    Diabetes Care; 2001 Nov; 24(11):2005-6. PubMed ID: 11679478
    [No Abstract]   [Full Text] [Related]  

  • 38. Allergic reactions to human insulin: a review of current knowledge and treatment options.
    Akinci B; Yener S; Bayraktar F; Yesil S
    Endocrine; 2010 Feb; 37(1):33-9. PubMed ID: 19876775
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of once-daily glargine insulin with twice-daily NPH/regular insulin for control of hyperglycemia in inpatients after cardiovascular surgery.
    Yeldandi RR; Lurie A; Baldwin D
    Diabetes Technol Ther; 2006 Dec; 8(6):609-16. PubMed ID: 17109592
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Basal insulin glargine vs prandial insulin lispro in type 2 diabetes.
    Oliveira JH; Kazda C; Simpson A; Jackson JA; Heine RJ
    Lancet; 2008 Aug; 372(9636):371-2; author reply 372. PubMed ID: 18675683
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.